CLINICAL_TRIALS
trial_result
· 2024-07-03
Clinical Trial Update: Oral ONC201 in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Summary
A Phase 1/2 trial evaluating oral ONC201 in relapsed/refractory multiple myeloma was terminated, with results posted in 2024.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Jazz Pharmaceuticals | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-07-03